(Reuters) -Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing ...

(Reuters) -Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to capitalize on Wall Street's insatiable ...

Metsera's MET-233i shows sustained weight loss, long duration of action, and mild side effects in a Phase 1 trial, advancing its obesity treatment plans.

This morning, Metsera, a new obesity biotech, reported that its GLP-1 drug led to substantial and durable weight loss in a Phase 1 study. The highest dose of the drug tested, 1.2 mg, was given ...

Preliminary four-week weight loss, tolerability, and pharmacokinetic data for the selected lead candidate are expected in late 2025. First Quarter 2025 Financial Results ...

Boosting Quality of Weight Loss Combining bimagrumab ... Juvena Therapeutics, Kallyope, Metsera, Morphic Medic/GI Dynamics, Novartis, Novo Nordisk, Pfizer, ProSciento, Senda Biosciences, Skye ...

(Reuters) -Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a U.S. initial public offering on Friday. The terms of the IPO were not ...

Metsera (NASDAQ:MTSR) stock jumps 16% as Wall Street continues to cheer positive Phase 1 data for its weight loss drug MET-233i. Read more here.

Metsera’s obesity drug candidate targeting the amylin hormone showed marked efficacy in an early trial and the potential to have longer-lasting effects than current weight loss treatments ...

Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo.

These data further substantiate HALO™, Metsera’s proprietary, novel peptide stabilization and lipidation platform technology. Body weight loss up to 8.4%.

Preliminary four-week weight loss, tolerability, and pharmacokinetic data for the selected lead candidate are expected in late 2025. First Quarter 2025 Financial Results ...